Zacks Research Issues Negative Forecast for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at Zacks Research dropped their Q1 2028 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Friday, June 26th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of ($1.22) per share for the quarter, down from their previous forecast of ($1.19). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.28) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ FY2028 earnings at ($4.34) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.Agios Pharmaceuticals’s revenue was up 137.7% on a year-over-year basis.

Other equities research analysts have also recently issued research reports about the stock. Truist Financial cut their price objective on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Citigroup raised their target price on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a report on Thursday, March 5th. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, HC Wainwright decreased their price objective on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $40.89.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $38.04 on Tuesday. The stock has a market capitalization of $2.26 billion, a P/E ratio of -5.25 and a beta of 0.59. The stock’s fifty day moving average is $29.51 and its 200 day moving average is $29.05. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bellevue Group AG increased its position in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after purchasing an additional 124,586 shares in the last quarter. State Street Corp boosted its position in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares in the last quarter. Erste Asset Management GmbH grew its stake in shares of Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after buying an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP grew its stake in shares of Agios Pharmaceuticals by 0.6% during the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after buying an additional 13,287 shares during the last quarter.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider James William Burns sold 3,280 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $113,848.80. Following the completion of the transaction, the insider owned 49,306 shares of the company’s stock, valued at approximately $1,711,411.26. The trade was a 6.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the transaction, the chief financial officer directly owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. The trade was a 5.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 12,623 shares of company stock valued at $438,144 in the last quarter. Corporate insiders own 5.40% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.